Cardiac Mapping Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 1.99 Billion |
| Market Size (2029) | USD 3.07 Billion |
| CAGR (2024 - 2029) | 8.99 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Cardiac Mapping Market Analysis
The Cardiac Mapping Market size is estimated at USD 1.99 billion in 2024, and is expected to reach USD 3.07 billion by 2029, growing at a CAGR of 8.99% during the forecast period (2024-2029).
Factors such as a rise in cardiac diseases and manufacturers' novel technological innovations in cardiac mapping devices are expected to drive market growth over the forecast period. As more individuals are diagnosed with coronary artery disease, there is a greater demand for precise diagnostic tools and technologies to assess the condition of the heart. For instance, as per the October 2022 update from the Center for Disease Control and Prevention (CDC), about 20.1 million adults aged 20 and older were diagnosed with coronary artery disease (about 7.2%) in the United States. Hence, with the high number of cardiac complications, the demand for cardiac mapping is expected to increase, boosting market growth over the forecast period.
Similarly, as per the BHF Global CVD Factsheet 2022, around 550 million people worldwide had heart and circulatory diseases in 2022. Thus, cardiac mapping plays a vital role in this process by providing detailed information about the heart's electrical activity and identifying abnormal rhythms or areas of concern. This is expected to further increase the demand for cardiac mapping, boosting market growth over the forecast period.
Product launches, strategic acquisitions, and partnerships by key players are further expected to increase product availability and competition in the market. For instance, in January 2022, Medtronic PLC entered a definitive agreement to acquire Affera Inc. at USD 925 million. Affera designs and manufactures cardiac mapping, navigation systems, and catheter-based cardiac ablation technologies. Similarly, in September 2022, Johnson & Johnson MedTech's subsidiary, Biosense Webster, unveiled its latest innovation, the Octaray mapping catheter. Thus, due to the rise in product approvals, launches, and technological advancements in cardiac mapping, the market studied is expected to grow significantly over the forecast period.
Therefore, factors such as the growing incidence of cardiac complications and manufacturers focusing on acquisition, approvals, and technological advancements for cardiac mapping are expected to fuel the market's growth during the forecast period. However, the lack of skilled electrophysiologists is likely to hinder the market's growth.
Cardiac Mapping Market Trends
Atrial Fibrillation Segment is Expected to Hold a Significant Market Share Over the Forecast Period
Cardiac mapping facilitates the identification of irregular heart rhythms (arrhythmias), including atrial fibrillation (AF). The increasing cases of heart failure, stroke, and other complications associated with AF underscores the importance of cardiac mapping, leading to substantial market growth projections for this segment.
The atrial fibrillation market is poised for substantial growth, driven by factors such as the rising prevalence of atrial fibrillation and increased demand for cardiac mapping in its treatment. Atrial fibrillation arises from a combination of a trigger that initiates an irregular heartbeat and a substrate that sustains it.
The high prevalence of atrial fibrillation (AFib) is a crucial driver for the growth of the cardiac mapping market. For instance, according to the data updated by the Centers for Disease Control and Prevention (CDC) in May 2024, 12.1 million Americans are expected to be affected by atrial fibrillation by 2030, and over 454,000 hospitalizations occur annually with atrial fibrillation as the primary diagnosis. Cardiac mapping is crucial for optimizing ablation techniques, allowing doctors to pinpoint triggers and substrates causing AFib and deliver targeted treatment. Thus, the high prevalence of atrial fibrillation globally is anticipated to fuel the market's growth over the forecast period.
Additionally, manufacturers focus on developing cardiac mapping and launching the product in the market. For instance, in August 2023, GE Healthcare launched CardioVisio, a digital tool designed to assist clinicians in visualizing longitudinal data essential for tracking the progression of Atrial Fibrillation (AFib) from diverse sources. Additionally, it offers evidence-based clinical decision support, aligning with the latest AFib guidelines. Thus, the rising initiatives by manufacturers, such as launches, are expected to drive the market's growth during the forecast period.
Furthermore, technological advancements in arrhythmia management are expected to drive market growth during the forecast period. For instance, according to an article published in Intechopen journal in May 2022, the advent of 3D electroanatomic mapping (EAM) and high-definition (HD) mapping significantly enhanced the safety and efficacy of ablation procedures, resulting in reduced procedural time and fluoroscopy exposure. Hence, the segment is expected to witness significant growth over the forecast period due to factors such as growing cases of atrial fibrillation and a rise in technological advances in cardiac mapping.
North America is Anticipated to Hold a Notable Market Share Over the Forecast Period
North America is expected to hold a significant market share during the forecast period due to the increase in healthcare expenditures, the growing burden of cardiac diseases, and the rise in product launches across North America. For instance, according to the American Heart Association (AHA), in February 2023, cardiac arrest in out-of-hospital remained a significant public health concern, accounting for approximately 350,000 fatalities annually in the United States. Additionally, as per the article published by PubMed in October 2022, an estimated 1000 adults in the United States experienced out-of-hospital cardiac arrest (OHCA) daily in 2022. Hence, the substantial prevalence of cardiac arrest in adults is anticipated to fuel market expansion during the projected period.
Similarly, the collaboration between the Canadian Institute for Health Information (CIHI) and the Canadian Cardiovascular Society (CCS) on the Cardiac Care Quality Indicators (CCQI) project has contributed to monitoring and improving critical areas related to cardiac care interventions across Canada. As a result, such initiatives are expected to drive market growth in the region during the forecast period.
Additionally, the expanding number of product approvals for cardiac mapping in North America is anticipated to be a key driver for the market's growth. For instance, in January 2022, Abbott secured FDA clearance for the EnSITE X EP system with EnSite Omnipolar Technology, a cardiac mapping platform. With the increasing prevalence of cardiac diseases and the proliferation of technological advancements, North America is expected to dominate a substantial portion of the global market throughout the forecast period.
Cardiac Mapping Industry Overview
The market is fragmented and consists of several major players. Key players are focused on strategic initiatives such as mergers, acquisitions, partnerships, and product launches to increase their global market presence. Biosense Webster Inc., Abbott, Medtronic, Boston Scientific Corporation, and Acutus Medical are some of the key players in the cardiac mapping market.
Cardiac Mapping Market Leaders
-
Medtronic Plc
-
Boston Scientific Corporation
-
Acutus Medical
-
Johnson & Johnson
-
Abbott
*Disclaimer: Major Players sorted in no particular order
Cardiac Mapping Market News
- May 2024: Biosense Webster Inc., a division of Johnson & Johnson MedTech, unveiled the CARTO 3 System Version 8. This upgraded iteration of the esteemed three-dimensional (3D) heart mapping system is designed for use in cardiac ablation procedures.
- July 2023: Biosense Webster Inc. launched the OPTRELL Mapping Catheter with TRUEref Technology in the United States, leveraging the CARTO 3 System.
Cardiac Mapping Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumption and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Incidence of Cardiovascular Complications
- 4.2.2 Rise in Technological Advancements in Cardiac Mapping Systems
-
4.3 Market Restraints
- 4.3.1 Lack of Skilled and Experienced Electrophysiologists
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Type
- 5.1.1 Contact Cardiac Mapping Systems
- 5.1.2 Non-contact Cardiac Mapping Systems
-
5.2 By Indication
- 5.2.1 Atrial Fibrillation
- 5.2.2 Atrial Flutter
- 5.2.3 Other Indications
-
5.3 By Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbott
- 6.1.2 Acutus Medical
- 6.1.3 Angiodynamics
- 6.1.4 APN Health LLC
- 6.1.5 Johnson & Johnson
- 6.1.6 Biosig Technologies Inc.
- 6.1.7 Boston Scientific Corporation
- 6.1.8 Kardium Inc.
- 6.1.9 Koninklijke Philips NV
- 6.1.10 Lepu Medical
- 6.1.11 Medtronic PLC
- 6.1.12 Microport Scientific Corporation
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityCardiac Mapping Industry Segmentation
As per the scope, cardiac mapping is an electrophysiology study that aims to understand the cause of heart rhythm problems like arrhythmia. Mapping the heart's electrical activity is critical for diagnosing and treating heart disease.
The cardiac mapping market is segmented by type, indication, and geography. By type, the market is segmented into contact cardiac mapping systems and non-contact cardiac mapping systems. By indication, the market is segmented into atrial fibrillation, atrial flutter, and other indications. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD) for the above segments.
| By Type | Contact Cardiac Mapping Systems | |
| Non-contact Cardiac Mapping Systems | ||
| By Indication | Atrial Fibrillation | |
| Atrial Flutter | ||
| Other Indications | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| By Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| By Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| By Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| By Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Cardiac Mapping Market Research FAQs
How big is the Cardiac Mapping Market?
The Cardiac Mapping Market size is expected to reach USD 1.99 billion in 2024 and grow at a CAGR of 8.99% to reach USD 3.07 billion by 2029.
What is the current Cardiac Mapping Market size?
In 2024, the Cardiac Mapping Market size is expected to reach USD 1.99 billion.
Who are the key players in Cardiac Mapping Market?
Medtronic Plc, Boston Scientific Corporation, Acutus Medical, Johnson & Johnson and Abbott are the major companies operating in the Cardiac Mapping Market.
Which is the fastest growing region in Cardiac Mapping Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Cardiac Mapping Market?
In 2024, the North America accounts for the largest market share in Cardiac Mapping Market.
What years does this Cardiac Mapping Market cover, and what was the market size in 2023?
In 2023, the Cardiac Mapping Market size was estimated at USD 1.81 billion. The report covers the Cardiac Mapping Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Cardiac Mapping Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Cardiac Mapping Industry Report
Statistics for the 2023 Cardiac Mapping market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Cardiac Mapping analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
